Lytix Biopharma ASA Balance Sheet

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	10.6	130.79	27.37	94.55	197.28
Short-Term Investments	61.76	-	23.18	50.61	-
Cash & Short-Term Investments	72.36	130.79	50.55	145.16	197.28
Cash Growth	-44.68%	158.75%	-65.18%	-26.42%	593.43%
Other Receivables	7.08	13.11	12.78	6.74	5.68
Total Trade Receivables	7.08	13.11	12.78	6.74	5.68
Total Current Assets	79.44	143.9	63.33	151.89	202.96
Net Property, Plant & Equipment	2.09	2.63	0.55	1.38	2.14
Total Assets	81.52	146.54	63.87	153.27	205.1
Accounts Payable	6.38	5.02	3.57	7	1.48
Current Portion of Leases	0.98	0.76	0.45	0.87	0.83
Other Current Liabilities	11.2	30.99	8.49	9.89	11.86
Total Current Liabilities	18.55	36.76	12.51	17.76	14.17
Long-Term Leases	1.22	1.88	0.04	0.48	1.34
Total Long-Term Liabilities	1.22	1.88	0.04	0.48	1.34
Total Liabilities	19.77	38.64	12.56	18.24	15.51
Common Stock	6.83	6.82	4.01	4.01	3.87
Additional Paid-in Capital	54.92	101.08	47.31	131.03	185.72
Total Common Shareholders' Equity	61.75	107.89	51.32	135.03	189.59
Shareholders' Equity	61.75	107.89	51.32	135.03	189.59
Total Liabilities & Equity	81.52	146.54	63.87	153.27	205.1
Total Debt	2.2	2.64	0.49	1.34	2.17
Net Cash (Debt)	70.16	128.15	50.06	143.81	195.11
Net Cash Growth	-45.25%	156.01%	-65.19%	-26.29%	585.80%
Net Cash Per Share	1.03	2.37	1.25	3.63	5.88
Book Value	61.75	107.89	51.32	135.03	189.59
Book Value Per Share	0.91	1.99	1.28	3.40	5.71
Tangible Book Value	61.75	107.89	51.32	135.03	189.59
Tangible Book Value Per Share	0.91	1.99	1.28	3.40	5.71